Emergingby GlyphRentosertib trial data read out on six proteomic aging clocks
Nature Biotechnology reported that six clocks indicated reduced predicted biological age in treated IPF patients.
Longevity biotechdoi.org
Insilico Medicine
Public companyHK1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechGenerative AI drug discovery company that tests candidates such as rentosertib against aging clocks. | Generative AI drug discovery company that tests candidates such as rentosertib against aging clocks. | insilico.com |
Events
Nature Medicine publishes Phase 2a trial of AI-discovered drug rentosertib
A randomized trial of the generative AI-discovered TNIK inhibitor in lung fibrosis was published.
Longevity biotechdoi.org
Insilico reports positive Phase 2a results for its AI-designed IPF drug
ISM001-055 was safe and showed dose-dependent gains in lung function at 12 weeks.
Longevity biotechinsilico.com
Funding
$293M
About
- Source
- insilico.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 13, 2026
- Across Glyph
- Insilico Medicine on Companies
Insilico Medicine
Joined in Longevity biotech. Generative AI drug discovery company that tests candidates such as rentosertib against aging clocks.
Insilico Medicine
Added in Longevity biotech. Generative AI drug discovery company that tests candidates such as rentosertib against aging clocks.